Seaport Global Advisors, LLC Exelixis, Inc. Transaction History

Seaport Global Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$19.04 - $22.74 $230,840 - $275,699	12,124 Added 86.93%	26,071 $569,000
Q1 2023 May 23, 2023	SELL	$16.3 - $19.41 $326,668 - $388,995	-20,041 Reduced 58.96%	13,947 $270,000
Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $447,737 - $520,465	29,929 Added 737.35%	33,988 $545,000
Q3 2022 Nov 21, 2022	SELL	$15.68 - $22.27 $148,520 - $210,941	-9,472 Reduced 70.0%	4,059 $64,000
Q2 2022 Aug 15, 2022	BUY	$17.44 - $23.16 $50,959 - $67,673	2,922 Added 27.54%	13,531 $282,000
Q1 2022 May 16, 2022	BUY	$17.03 - $22.67 $180,671 - $240,506	10,609 New	10,609 $241,000

502

243M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.9B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Seaport Global Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Seaport Global Advisors, LLC with notifications on news.